Latest & greatest articles for rheumatoid arthritis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on rheumatoid arthritis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on rheumatoid arthritis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for rheumatoid arthritis

161. Is the serum oxytocin level altered by treatment in rheumatoid arthritis patients complicated with depression? (PubMed)

Is the serum oxytocin level altered by treatment in rheumatoid arthritis patients complicated with depression? The objective of this study was to investigate the factors associated with depression, including serum oxytocin (OXT) levels, disease activity, activities of daily living (ADL), and quality of life (QOL), and their effects on rheumatoid arthritis (RA).This study included 42 RA patients who received treatment with a biological agent. We measured the following variables before and after

Full Text available with Trip Pro

2018 European journal of rheumatology

162. Tapering versus steady-state methotrexate in combination with tocilizumab for rheumatoid arthritis: a randomized, double-blind trial

Tapering versus steady-state methotrexate in combination with tocilizumab for rheumatoid arthritis: a randomized, double-blind trial To explore whether tocilizumab + tapering MTX has comparable efficacy and safety vs tocilizumab + stable MTX in adult RA patients with inadequate response to MTX.This randomized, placebo-controlled non-inferiority study involved patients with severe active RA [28-joint DAS (DAS28) >5.1] who had initiated tocilizumab + MTX at the study start. Patients received open

Full Text available with Trip Pro

2018 EvidenceUpdates

163. Physical Activity to Reduce Fatigue in Rheumatoid Arthritis: A Randomized Controlled Trial

Physical Activity to Reduce Fatigue in Rheumatoid Arthritis: A Randomized Controlled Trial Effective treatments for rheumatoid arthritis (RA) fatigue are limited. We tested the effect of a pedometer-based intervention on increasing physical activity and decreasing fatigue among individuals with RA.Participants completed baseline questionnaires; had 1 week of activity monitoring; were randomized to control (education [EDUC]), pedometer and step-monitoring diary (PED), or pedometer and diary plus

Full Text available with Trip Pro

2018 EvidenceUpdates

164. Rheumatoid arthritis patients treated in trial and real world settings: comparison of randomized trials with registries

Rheumatoid arthritis patients treated in trial and real world settings: comparison of randomized trials with registries To investigate whether patients with RA enrolled in randomized controlled trials (RCTs) and observational studies may differ in terms of characteristics that could modify treatment effects, leading to an efficacy-effectiveness gap.We conducted systematic literature reviews to identify RCTs and observational studies with RA, treated with rituximab, tocilizumab or etanercept. We

Full Text available with Trip Pro

2018 EvidenceUpdates

165. Radiographic joint damage in early rheumatoid arthritis patients: comparing tocilizumab- and methotrexate-based treat-to-target strategies

Radiographic joint damage in early rheumatoid arthritis patients: comparing tocilizumab- and methotrexate-based treat-to-target strategies To evaluate the progression of erosions and joint space narrowing (JSN) in feet and hands in the U-Act-Early trial.In this trial, 317 newly diagnosed DMARD-naïve RA patients initiated randomly tocilizumab, or step-up MTX or a combination of the two. Radiographs were scored at baseline and after 52 and 104 weeks using the Sharp-van der Heijde erosion and JSN

2018 EvidenceUpdates

166. Effectiveness of an overall progressive resistance strength program for improving the functional capacity of patients with rheumatoid arthritis: a randomized controlled trial

Effectiveness of an overall progressive resistance strength program for improving the functional capacity of patients with rheumatoid arthritis: a randomized controlled trial To evaluate the effectiveness of overall progressive resistance training in patients with rheumatoid arthritis.Randomized controlled clinical trial with blinded assessor and intention-to-treat analysis.Outpatient clinics.Sixty patients with rheumatoid arthritis according to the American College of Rheumatology criteria

2018 EvidenceUpdates

167. Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis Population. (PubMed)

Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis Population. In Australia, there is an unmet need for improved treatments for rheumatoid arthritis (RA). Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. To provide an overview of key study outcomes for tofacitinib in Australian patients, we analyzed the efficacy and safety of tofacitinib in the Australian subpopulation of global RA phase III and long-term

Full Text available with Trip Pro

2018 Rheumatology and therapy

168. Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc Analyses. (PubMed)

Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc Analyses. Here we examine the relationship between achieving different levels of disease activity with tofacitinib (an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis), long-term structural progression, and patient-reported physical function.This was a post hoc analysis of two 24-month, phase III randomized controlled trials

Full Text available with Trip Pro

2018 Rheumatology and therapy

169. Rheumatoid arthritis

Rheumatoid arthritis Rheumatoid arthritis - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Rheumatoid arthritis Last reviewed: February 2019 Last updated: September 2018 Summary A chronic, erosive arthritis that requires early and aggressive treatment. Diagnosed clinically. Laboratory and radiographic testing provide prognostic information more often than diagnostic information. Methotrexate is the anchor drug (...) for the treatment of RA. Disease activity scores (e.g., 28-joint count version of disease activity score [DAS28], clinical disease activity index [CDAI], simplified disease activity index [SDAI], routine assessment patient index data [RAPID3]) are used routinely to provide optimum care for RA patients. Definition Rheumatoid arthritis (RA) is a chronic inflammatory condition affecting around 1% of the population, making it the most common inflammatory arthritis seen by physicians. Lee DM, Weinblatt ME

2018 BMJ Best Practice

170. Tofacitinib (rheumatoid arthritis) - Addendum to Commission A17-18

Tofacitinib (rheumatoid arthritis) - Addendum to Commission A17-18 1 Translation of addendum A17-43 Tofacitinib (rheumatoide Arthritis) – Addendum zum Auftrag A17-18 (Version 1.0; Status: 28 September 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 28 September 2017 1.0 Commission: A17-43 Version: Status: IQWiG Reports – Commission No. A17-43 (...) Tofacitinib (rheumatoid arthritis) – Addendum to Commission A17-18 1 Addendum A17-43 Version 1.0 Tofacitinib – Addendum to Commission A17-18 28 September 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Tofacitinib (rheumatoid arthritis) – Addendum to Commission A17-18 Commissioning agency: Federal Joint Committee Commission awarded on: 4 September 2017 Internal Commission No.: A17-43 Address

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

171. Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response

Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response In SELECT-COMPARE, a randomised double-blind study, upadacitinib 15 mg once daily was superior to placebo or adalimumab on background methotrexate (MTX) for treating rheumatoid arthritis signs and symptoms and inhibited radiographical progression versus placebo at 26 weeks. Here we report 48-week

Full Text available with Trip Pro

2018 EvidenceUpdates

172. Drugs for the Management of Rheumatoid Arthritis

Drugs for the Management of Rheumatoid Arthritis Drugs for the Management of Rheumatoid Arthritis | CADTH.ca Find the information you need Drugs for the Management of Rheumatoid Arthritis Drugs for the Management of Rheumatoid Arthritis Published on: April 25, 2018 Project Number: HT0010-000 Product Line: Result type: Report Key Messages For rheumatoid arthritis patients with moderate to severe disease in whom treatment with methotrexate has failed or who are intolerant to methotrexate (...) of the next treatment option should be based on a discussion between the clinician and patient that takes into consideration benefits and harms, patient treatment goals and tolerance for side effects, accessibility of treatment (e.g., whether travel is necessary), and affordability. Context Rheumatoid arthritis (RA) is a chronic inflammatory disease that affects joints throughout the body, causing pain, swelling, stiffness, and joint damage. Approximately 300,000 Canadians have RA. Untreated, it can lead

2018 CADTH - Health Technology Assessment

173. Conventional Synthetic Disease-Modifying Antirheumatic Drugs for Adults with Moderate to Severe Rheumatoid Arthritis: Clinical Effectiveness

Conventional Synthetic Disease-Modifying Antirheumatic Drugs for Adults with Moderate to Severe Rheumatoid Arthritis: Clinical Effectiveness Conventional Synthetic Disease-Modifying Antirheumatic Drugs for Adults with Moderate to Severe Rheumatoid Arthritis: Clinical Effectiveness | CADTH.ca Find the information you need Conventional Synthetic Disease-Modifying Antirheumatic Drugs for Adults with Moderate to Severe Rheumatoid Arthritis: Clinical Effectiveness Conventional Synthetic Disease (...) -Modifying Antirheumatic Drugs for Adults with Moderate to Severe Rheumatoid Arthritis: Clinical Effectiveness Last updated: June 12, 2018 Project Number: RA0956-000 Product Line: Research Type: Drug Report Type: Reference List Result type: Report Question What is the clinical effectiveness of conventional synthetic disease-modifying antirheumatic drugs in adult patients with moderate to severe rheumatoid arthritis? Key Message Five systematic reviews (two with meta-analyses and one with a network meta

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

174. Rituximab Maintenance Therapy for the Treatment and Management of Rheumatoid Arthritis: A Review of Clinical Effectiveness

Rituximab Maintenance Therapy for the Treatment and Management of Rheumatoid Arthritis: A Review of Clinical Effectiveness Rituximab Maintenance Therapy for the Treatment and Management of Rheumatoid Arthritis: A Review of Clinical Effectiveness | CADTH.ca Find the information you need Rituximab Maintenance Therapy for the Treatment and Management of Rheumatoid Arthritis: A Review of Clinical Effectiveness Rituximab Maintenance Therapy for the Treatment and Management of Rheumatoid Arthritis (...) : A Review of Clinical Effectiveness Last updated: July 4, 2018 Project Number: RC0997-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of rituximab maintenance therapy for the treatment and management of rheumatoid arthritis? Key Message Five non-randomized studies were included in this review, of which three were single-arm studies and two were comparative cohorts. The studies were of poor quality overall

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

175. csDMARDs for Rheumatoid Arthritis

csDMARDs for Rheumatoid Arthritis csDMARDs for Rheumatoid Arthritis | CADTH.ca Find the information you need csDMARDs for Rheumatoid Arthritis csDMARDs for Rheumatoid Arthritis Last updated: October 30, 2018 Project Number: OP0539-000 Product Line: Project Status: Cancelled Result type: Report The project OP0539 csDMARDs for Rheumatoid Arthritis will not be conducted as proposed due to changes in the needs of the jurisdictional customer. As a result, the objectives and needs are being

2018 CADTH - Optimal Use

176. Triple csDMARDs for Rheumatoid Arthritis

Triple csDMARDs for Rheumatoid Arthritis Triple csDMARDs for Rheumatoid Arthritis | CADTH.ca Find the information you need Triple csDMARDs for Rheumatoid Arthritis Triple csDMARDs for Rheumatoid Arthritis Last updated: October 9, 2019 Project Number: OP0543-000 Product Line: Project Status: Cancelled Result type: Report The project OP0543 Triple csDMARDs for Rheumatoid Arthritis will not be conducted as proposed due to changes in the needs of the jurisdictional customer. As a result

2018 CADTH - Optimal Use

177. Relationship between cartilage oligomeric matrix protein (COMP) and rheumatoid arthritis severity (PubMed)

Relationship between cartilage oligomeric matrix protein (COMP) and rheumatoid arthritis severity Serum cartilage oligomeric matrix protein (COMP) is a non-collagen glycoprotein produced by the cartilage, synovium, tendon, and meniscus. Recent studies showed that COMP is a reliable factor for monitoring cartilage damage.To determine the relationship between serum COMP concentration and the severity of rheumatoid arthritis (RA).This cross-sectional study lasted from 2013 to 2015

Full Text available with Trip Pro

2017 Electronic physician

178. Usability and Patient Preference Phase 3 Study of the Sarilumab Pen in Patients with Active Moderate-to-Severe Rheumatoid Arthritis (PubMed)

Usability and Patient Preference Phase 3 Study of the Sarilumab Pen in Patients with Active Moderate-to-Severe Rheumatoid Arthritis Sarilumab is a human monoclonal antibody that blocks the interleukin-6 receptor alpha (IL-6Rα). The phase 3 SARIL-RA-EASY study (EASY) assessed the robustness of an autoinjector (pen) for administering sarilumab when used by adults with active moderate-to-severe rheumatoid arthritis (RA) who are candidates for anti-IL-6R therapy in an unsupervised real-world

Full Text available with Trip Pro

2017 Rheumatology and therapy

179. A Retrospective Analysis of Corticosteroid Utilization Before Initiation of Biologic DMARDs Among Patients with Rheumatoid Arthritis in the United States (PubMed)

A Retrospective Analysis of Corticosteroid Utilization Before Initiation of Biologic DMARDs Among Patients with Rheumatoid Arthritis in the United States Understanding the effects of corticosteroid utilization prior to initiation of biologic disease-modifying antirheumatic drugs (DMARDs) can inform decision-makers on the appropriate use of these medications. This study examined treatment patterns and associated burden of corticosteroid utilization before initiation of biologic DMARDs among (...) rheumatoid arthritis (RA) patients.A retrospective analysis was conducted of adult RA patients in the US MarketScan Database (2011-2015). The following patterns of corticosteroid utilization were analyzed: whether corticosteroids were used; duration of use (short/long duration defined as < or ≥ 3 months); and dosage (low as < 2.5, medium as 2.5 to < 7.5 and high as ≥ 7.5 mg/day). Effects of corticosteroid use on time to biologic DMARD initiation were examined using Cox proportional hazards models

Full Text available with Trip Pro

2017 Rheumatology and therapy

180. Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis

Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis To assess the risk of losing remission, low disease activity (LDA) or radiographic progression in the case of (1) discontinuing or (2) tapering doses of biological disease-modifying antirheumatic drugs (bDMARDs) compared with continuation of the initial treatment regimen in rheumatoid arthritis

2017 EvidenceUpdates